Special Issue

Metabolism and Metabolic Targeting of Neuroblastoma

Message from the Guest Editors

Neuroblastoma is one of the most common pediatric cancers that remains incurable in about 50% of children in high-risk stages despite aggressive multimodal treatment strategies. Even when patients survive, they usually have a high morbidity due to the side effects of intensive therapies, and are at risk of tumor recurrence. Alterations in metabolic pathways such as glycolysis, mitochondrial respiration and lipid as well as amino acid metabolism are recognized hallmarks of neuroblastoma that contribute to tumor progression and interact with the tumor microenvironment, influencing the response and resistance to therapies. Therefore, therapeutics targeting different facets of tumor metabolism are considered new and effective options to improve the efficacy of standard cancer therapies such as chemo-, radio-, and immunotherapy, and to mitigate the side effects of such therapies. This Special Issue of *Metabolites* presents the latest research on metabolism in neuroblastoma and therapeutic options in this area.

Guest Editors

Dr. Sepideh Aminzadeh-Gohari

Research Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, University Hospital of the Paracelsus Medical University, 5020 Salzburg, Austria

Prof. Dr. Barbara Kofler

Research Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, Paracelsus Medical University, 5020 Salzburg, Austria

Deadline for manuscript submissions

closed (30 September 2023)

Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed

mdpi.com/si/129070

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/metabolites



Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed

mdpi.com/journal/metabolites

MDPI

About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo
Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).